{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":23,"n_cols":5,"rows_kept":23,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[6,2,6,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[17,2,17,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910297034703321"]
[null,null,"Autore",null,"Ahn Hyewon"]
[null,null,"Titolo",null,"Patentability of Chemical Selection Inventions"]
[null,null,"Pubbl/distr/stampa",null,"Nomos Verlagsgesellschaft mbH & Co. KG, 2011"]
[{"$nulls":4},"La Vergne : , : e-book, , 2024"]
[{"$nulls":4},"©2024"]
[null,null,"ISBN",null,"9783845232188"]
[{"$nulls":4},"3845232188"]
[null,null,"Edizione",null,"[First edition.]"]
[null,null,"Descrizione fisica",null,"1 online resource (75 pages) : illustrations"]
[null,null,"Collana",null,"Munich Intellectual Property Law Center - MIPLC."]
[null,null,"Soggetti",null,"Drugs"]
[{"$nulls":4},"Patent laws and legislation"]
[{"$nulls":4},"Conflict of laws - Patents"]
[{"$nulls":4},"Drug development"]
[{"$nulls":4},"Olanzapine"]
[{"$nulls":4},"Citalopram"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Originally presented as the author's thesis--Universität München, 2010."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references (pages 69-75)."]
[null,null,null,"Sommario/riassunto","The thesis is a response to the recent decisions of the German Federal Court of Justice on the patentability requirements of selection inventions, namely, the Olanzapine and Escitalopram decisions."]